NPPB and hydrops fetalis: The clinical benefit of titrating therapy according to NP levels was tested in a landmark study by Troughton et al. [118] patients with decompensated HF and ejection fractions of <40% were recruited to test the hypothesis that any treatment that decreases NT-proBNP levels to <200 pmol/L (approximately 1700 ng/L) would reduce cardiac events.